OvaScience, Inc. (OVAS) Milestone Rewards Option Bulls

OvaScience Inc's (OVAS) Augment fertility treatment produced its first birth

May 7, 2015 at 2:55 PM
facebook X logo linkedin


OvaScience Inc (NASDAQ:OVAS) traders have been buying to open calls at a breakneck pace recently. The fertility stock's 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 8.13. In other words, more than eight OVAS calls have been bought to open for every put over the last two weeks.

Elsewhere on the Street, 100% of analysts tracking the security rate it a "strong buy." What's more, OVAS' consensus 12-month price target of $64 represents a 148.6% premium to the current price of $25.74-- as well as never-before-charted waters.

Today's strong price action is vindicating these optimists. At last check, OVAS shares were 4.8% higher, after the company's Augment fertility treatment produced its first-ever birth. Longer term, though, the picture isn't so rosy. OvaScience Inc (NASDAQ:OVAS) has plunged 41.5% year-to-date.
 

Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.


Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!

 

 
 
 


 
 

Rainmaker Ads CGI